Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-0610 in previously treated multiple myeloma
NCT02157636Phase 1Completed
- Sponsor
- Constellation Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of pelabresib in multiple myeloma (MM), sponsored by Constellation Pharmaceuticals. Primary endpoint: Frequency of dose-limiting toxicities. Started Jul 2014; status: completed.
02
Drugs
pelabresib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02157636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157636.